Latest Pharma Insights
EC Fails To Address ‘Flawed Data’ On Cosmetics’ Contribution To Wastewater Pollution - Industry
An updated study on the extended producer responsibility costs associated with the Urban Wastewater Treatment Directive, released with the latest omnibus from the European Commission focusing on the environment, doesn't adjust the cosmetic industry’s expected financial contribution.
HBW Insight - December 18, 2025
An updated study on the extended producer responsibility costs associated with the Urban Wastewater Treatment Directive, released with the latest omnibus from the European Commission focusing on the environment, doesn't adjust the cosmetic industry’s expected financial contribution.
HBW Insight - December 18, 2025
Oncolys’s 20-Year Journey To First Approval Filing
Oncolys reaches hard-won milestone with an approval filing in Japan for its oncolytic virus therapy telomelysin through the sakigake pathway, with the Japanese venture eyeing its first commercial launch in 2026.
Scrip - December 18, 2025
Oncolys reaches hard-won milestone with an approval filing in Japan for its oncolytic virus therapy telomelysin through the sakigake pathway, with the Japanese venture eyeing its first commercial launch in 2026.
Scrip - December 18, 2025
Oncolys’s 20-Year Journey To First Approval Filing
Oncolys reaches hard-won milestone with an approval filing in Japan for its oncolytic virus therapy telomelysin through the sakigake pathway, with the Japanese venture eyeing its first commercial launch in 2026.
Scrip - December 18, 2025
Oncolys reaches hard-won milestone with an approval filing in Japan for its oncolytic virus therapy telomelysin through the sakigake pathway, with the Japanese venture eyeing its first commercial launch in 2026.
Scrip - December 18, 2025
Consultant: Medicare Payment Changes May Expand Home Cardiac Monitoring and Reshape RPM Market
Medicare's new cardiac monitoring payment updates are set to boost home monitoring adoption by easing billing processes and improving reimbursement rates. The changes may benefit providers directly, shifting control from diagnostic testing facilities and potentially reshaping the RPM market.
Medtech Insight - December 17, 2025
Medicare's new cardiac monitoring payment updates are set to boost home monitoring adoption by easing billing processes and improving reimbursement rates. The changes may benefit providers directly, shifting control from diagnostic testing facilities and potentially reshaping the RPM market.
Medtech Insight - December 17, 2025
Medtech Outlook 2026: AI Integration Deepens As M&A Fuels Growth
Medtech leaders expect faster change in 2026 as AI integration speeds up across all business aspects, according to a Deloitte survey of medtech execs that also predicted M&A activity will remain strong in 2026. While optimism is high, uncertainties remain.
Medtech Insight - December 17, 2025
Medtech leaders expect faster change in 2026 as AI integration speeds up across all business aspects, according to a Deloitte survey of medtech execs that also predicted M&A activity will remain strong in 2026. While optimism is high, uncertainties remain.
Medtech Insight - December 17, 2025
MHRA And HSA Lay UK-Singapore Path To Closer Medtech Harmonization – ‘But SMEs Take Heed’
Joint Singapore-UK plan underlines direction of travel for MHRA after its embracing of international reliance (IR). Australia’s TGA has also broken new ground by recognizing the UKCA mark.
Medtech Insight - December 17, 2025
Joint Singapore-UK plan underlines direction of travel for MHRA after its embracing of international reliance (IR). Australia’s TGA has also broken new ground by recognizing the UKCA mark.
Medtech Insight - December 17, 2025
Fragmented Governance Must Be Tackled As Part Of EU Medtech Revision
Industry associations support the commission’s MDR/IVDR revision simplification objective and aim to increase Europe’s competitiveness, but MedTech Europe also sees further room for improvement.
Medtech Insight - December 17, 2025
Industry associations support the commission’s MDR/IVDR revision simplification objective and aim to increase Europe’s competitiveness, but MedTech Europe also sees further room for improvement.
Medtech Insight - December 17, 2025
EC Fails To Address ‘Flawed Data’ On Cosmetics’ Contribution To Wastewater Pollution - Industry
An updated study on the extended producer responsibility costs associated with the Urban Wastewater Treatment Directive, released with the latest omnibus from the European Commission focusing on the environment, doesn't adjust the cosmetic industry’s expected financial contribution.
HBW Insight - December 18, 2025
An updated study on the extended producer responsibility costs associated with the Urban Wastewater Treatment Directive, released with the latest omnibus from the European Commission focusing on the environment, doesn't adjust the cosmetic industry’s expected financial contribution.
HBW Insight - December 18, 2025
Alvotech Quietly Flags Aflibercept CRL Alongside $100m-Plus Financing
The FDA rejection of Alvotech’s AVT06 Eylea biosimilar was revealed as part of a wider funding update outlining a $108m bond placement and continued heavy R&D investment.
Generics Bulletin - December 17, 2025
The FDA rejection of Alvotech’s AVT06 Eylea biosimilar was revealed as part of a wider funding update outlining a $108m bond placement and continued heavy R&D investment.
Generics Bulletin - December 17, 2025
New CEO Sonig Leads Rosemont Towards US Ambitions
UK liquids specialist Rosemont Pharmaceuticals has named industry veteran Alok Sonig as its new CEO, as the firm continues to set its sights on the US market. Meanwhile, Rosemont has also appointed Gavin Wood as chief financial officer.
Generics Bulletin - December 17, 2025
UK liquids specialist Rosemont Pharmaceuticals has named industry veteran Alok Sonig as its new CEO, as the firm continues to set its sights on the US market. Meanwhile, Rosemont has also appointed Gavin Wood as chief financial officer.
Generics Bulletin - December 17, 2025
Sun Pharma Mirrors Dr Reddy’s Outcome In Novo Nordisk Semaglutide Litigation
Decision matches earlier Dr Reddy’s outcome, although no injunctive action involved, allowing exports to non-patent markets ahead of a post-expiry launch.
Generics Bulletin - December 17, 2025
Decision matches earlier Dr Reddy’s outcome, although no injunctive action involved, allowing exports to non-patent markets ahead of a post-expiry launch.
Generics Bulletin - December 17, 2025
Selective Risk Taking: Cell And Gene Therapy’s Phoenix Moment
Investors and analysts say cell and gene therapy is entering a disciplined “phoenix” phase, with selective risk taking, AI enabled platforms and new pricing models redefining how one time cures attract capital.
In Vivo - December 15, 2025
Investors and analysts say cell and gene therapy is entering a disciplined “phoenix” phase, with selective risk taking, AI enabled platforms and new pricing models redefining how one time cures attract capital.
In Vivo - December 15, 2025
Deals In Depth: November 2025
Four $1bn+ alliances were penned in November, and three exceeded $2bn. In the top alliance by deal value, Valo Health entered into a potential $3bn collaboration with Merck KGaA to advance therapeutic discovery in Parkinson’s disease and related disorders.
In Vivo - December 15, 2025
Four $1bn+ alliances were penned in November, and three exceeded $2bn. In the top alliance by deal value, Valo Health entered into a potential $3bn collaboration with Merck KGaA to advance therapeutic discovery in Parkinson’s disease and related disorders.
In Vivo - December 15, 2025
Biogen Doubles Down On Immunology As Lupus Programs Near Readouts
With two late-stage lupus assets finishing recruitment and a newly acquired nephrology franchise running three concurrent Phase III programs, Biogen is making its most significant commitment yet to immunology beyond its legacy MS business.
In Vivo - December 15, 2025
With two late-stage lupus assets finishing recruitment and a newly acquired nephrology franchise running three concurrent Phase III programs, Biogen is making its most significant commitment yet to immunology beyond its legacy MS business.
In Vivo - December 15, 2025